Peking University

Other

Institute of Pharmacology and Toxicology Academy of Military Medical Science P.l.a. China

Beijing Medical University

Beijing Medical University United Biological Engineering Company

Institute of Pharmacology and Toxicology Academy of Military Medical Sciences Pla China

Dalong Ma

Wenling Han

Ying Wang

Jian Tang

Guanghui Chen

Jiaqiang Huang

Yingmei Zhang

Quansheng Song

Chunhui Di

Yang Zhang

Lili Wang

Song Li

Wu Zhong

Dan Li

Junhai Xiao

Zhibing Zheng

Jing Yan Ma

Xinbo Zhou

Xingzhou Li

Yunde Xie

Xiaokui Wang

Guoming Zhao

Yanan Liu

Hongying Liu

Hui Qi

Jing Ma

Hongwei Gong

Xiaomei Ling

Meina Li

Enquan Xu

Caihua Yin

Linjie Tian

Yingme Zhang

Provided are piperazinyl pyrimidine derivatives of formula I having CCRantagonism, and the preparation method, pharmaceutical composition and use thereof in the preparation of a medicament. The medicament is useful for the treatment and prevention of CCR-related diseases. 

Piperazinyl pyrimidine derivatives, preparation method and use thereof

Polypeptides having an amino acid sequence of SEQ ID NO: 2, and having amino acid residues 9 to 27 of SEQ ID NO: 2 are disclosed, which are together named C-terminal polypeptides of CKLF1. Also disclosed is a pharmaceutical composition containing a therapeutically effective amount of the CKLF1 C-terminal polypeptide and pharmaceutically acceptable salts, carrier or excipient. Further disclosed are the polynucleotides encoding the C-terminal polypeptides of CKLF1, and vectors and host cells containing the polynucleotides; the in vitro assays for detecting the expression level of the polypeptide or polynucleotide in a test sample; and the monoclonal or polyclonal antibodies against the polypeptides or active fragments thereof. The polypeptides of the present invention can be pharmaceutically used for treating the HIV infection, allergic disease, allograft rejection, diseases in brain and autoimmune diseases.

Polypeptide fragments of CKLF1

The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.

Chemokine-like factors (CKLFs) with chemotactic and hematopoietic stimulating activities

Nucleic acid molecule encoding chemokine-like factor 1 (CKLF1)

Growing community of inventors

Beijing, China

Dalong Ma